![switching between glp-1 agonists Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance PDF] Switching Between Glucagon-Like Peptide-1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78fb/7566932/5708c04e47e2/diaclincd190100f2.jpg)
switching between glp-1 agonists Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance PDF] Switching Between Glucagon-Like Peptide-1
Description
This landscape features major pharmaceutical companies developing GLP-1 therapies, service providers supporting clinical trials, regulatory agencies overseeing safety and efficacy, and end users such as hospitals, clinics, and home care settings
![switching between glp-1 agonists Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance PDF] Switching Between Glucagon-Like Peptide-1](https://figures.semanticscholar.org/69d84ad0979bcded8fc643f42a28ce77fbc5b3ff/4-Table2-1.png)
2024;7(7):e2421305
![switching between glp-1 agonists Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance PDF] Switching Between Glucagon-Like Peptide-1](https://framerusercontent.com/images/Bop1y2U6iBNlBo6usW8zPBEOqY.png)
The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor
![switching between glp-1 agonists Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance PDF] Switching Between Glucagon-Like Peptide-1](https://cdn.sanity.io/images/0vv8moc6/ajmc/4591eca94c600eae8308f44c44ec95c55d86a2fe-1200x738.jpg)
Opportunities lie in expanding drug applications beyond diabetes, focusing on weight management in non-diabetic individuals
![switching between glp-1 agonists Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance PDF] Switching Between Glucagon-Like Peptide-1](https://www.mdpi.com/ijms/ijms-27-02853/article_deploy/html/images/ijms-27-02853-g002-550.jpg)
